Two types of pharmacotherapy are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA). Maintenance therapies are inhaled, oral, or biological drugs that are used to prevent exacerbations by targeting the underlying pathophysiology (e.g., a LABA/ICS such as GlaxoSmithKline’s Advair, an anti-IL-5 agent such as AstraZeneca’s Fasenra). Many adult patients receive several agents to treat their asthma. Although multiple well-established therapies are available, the market has seen the approval and launch of even more agents, including novel biologics (e.g., AstraZeneca’s Tezspire) and generic versions of blockbuster inhaled drugs (e.g., albuterol sulfate, formoterol / budesonide). These launches have added treatment options and fueled more-intense competition in this market.
Questions answered
Content highlights
Markets covered: United States
Key companies: GlaxoSmithKline, AstraZeneca, Teva, Genentech, Merck, Boehringer Ingelheim, Sanofi, Regeneron, Mylan, Cipla, Par, Perrigo, Prasco
Key drugs: Advair, Symbicort, Dulera, AirDuo, Breo, Dupixent, Fasenra, Nucala, Ventolin, ProAir, montelukast sodium, Flovent, Qvar, Spiriva, Tezspire, Trelegy
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key Feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses